Literature DB >> 10608354

Analysis of the human carcinoembryonic antigen promoter core region in colorectal carcinoma-selective cytosine deaminase gene therapy.

G Cao1, S Kuriyama, L Cui, S Nagao, X Pan, Y Toyokawa, X Zhang, I Nishiwaki, Z Qi.   

Abstract

We isolated a 204-base pair carcinoembryonic antigen (CEA) promoter core region from a CEA-producing human colorectal carcinoma (CRC) and constructed retrovirus vectors carrying the expression cassette consisting of the CEA promoter core region and the cytosine deaminase (CD) gene. pCD2 retrovirus carrying the CD gene directed by the retrovirus long terminal repeat promoter served as a control vector. An in vitro study showed that the CEA promoter conferred CEA-producing cell-selective CD expression, specifically when the CD expression cassette was inserted into the 3' long terminal repeat of the retrovirus vector. CD-modified CRC xenografts in nude mice were sensitive to 5-fluorocytosine and caused a profound bystander effect on the unmodified CRC. When nude mice harboring intraperitoneally disseminated CRCs were injected intraperitoneally with the CD expression cassette-carrying retrovirus-producing cells, CD transduction into the disseminated CRCs and bone marrow (BM) was observed. CD expression was, however, restricted to CRCs, and it was observed in both CRCs and BM of mice injected with pCD2 retrovirus-producing cells, resulting in better therapeutic outcomes without BM suppression. These results indicate that effective and safe in vivo gene therapy for CRC may be feasible by transferring the CD gene controlled by the CEA promoter core region.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10608354     DOI: 10.1038/sj.cgt.7700082

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  3 in total

1.  CMV enhancer may not be suitable for tissue-specific enhancement of promoters in cancer gene therapy.

Authors:  Jing Jia; Shuzhi Zhang; Zhenyu Jia; Jiang Cao
Journal:  Cancer Gene Ther       Date:  2019-05-27       Impact factor: 5.987

2.  Electrochemotherapy for colorectal cancer with commonly used chemotherapeutic agents in a mouse model.

Authors:  S Kuriyama; M Matsumoto; A Mitoro; H Tsujinoue; T Nakatani; H Fukui; T Tsujii
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

3.  Expression of thymidine kinase mediated by a novel non-viral delivery system under the control of vascular endothelial growth factor receptor 2 promoter selectively kills human umbilical vein endothelial cells.

Authors:  Ying Wang; Hui-Xiong Xu; Ming-De Lu; Qing Tang
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.